| abstract |
Treatment of cancer in a patient comprises administering to the patient an antibody and a non-antibody agent that activates the patient's own NK cells, wherein the antibody binds an antigen on the surface of the patient's own NK cells and the antibody Fc region binds to an Fc receptor on a cell of the cancer. Anticancer activity is via resultant killing action of the NK cell on the cancer cell, now binding the antibody Fc region, via reverse antibody-dependent cell-mediated cytotoxicity (R-ADCC). |